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ABSTRACT
Purpose: EGR-1 is an immediate early gene with di-
verse functions that include the suppression of growth.
EGR-1 is down-regulated many cancer cell types, suggesting
a tumor suppressor role, and may critically involve the p53
pathway. The aim of this work was to measure the expres-
sion of EGR-1 and the p16/INK4a/ARF-Mdm2-p53 pathway
status in fresh human gliomas.
Experimental Design: Thirty-one human gliomas with
different grades of malignancy were investigated for Egr-1
mRNA and the protein expression, frequency, and spectrum
of p53 gene mutations, mdm2 gene amplification, and p16/
INK4a/ARF allele loss.
Results: The amplification of Mdm2 and the deletion
of the p16/INK4a gene was found in 3 and 5 cases, respec-
tively, whereas mutations of p53, including two novel
mutations, were observed in 10 other cases. The three
types of changes occurred strictly mutually exclusively,
emphasizing that these genes operate in a common path-
way critical to glioma progression. EGR-1 mRNA was
significantly down-regulated in astrocytomas (14.7 
5.1%) and in glioblastomas (33.6  10.0%) versus normal
brain. Overall, EGR-1 mRNA was strongly suppressed
(average, 15.2  13.9%) in 27 of 31 cases (87%), inde-
pendent of changes in p16/INK4a/ARF and Mdm2;
whereas 4 of 31 cases with residual EGR-1 expression as
well as the highest EGR-1 variance segregated with p53
mutations. Immunohistochemical analyses confirmed the
suppression of EGR-1 protein.
Conclusions: These results indicate that EGR-1 is com-
monly suppressed in gliomas independent of p16/INK4a/
ARF and Mdm2 and that suppression is less crucial in
tumors bearing p53 mutations, and these results implicate
an EGR-1 growth regulatory mechanism as a target of
inactivation during tumor progression.
INTRODUCTION
Several important genes with tumor suppressive functions
have been implicated for the pathogenesis of astrocytic neo-
plasms (1, 2). Mutational inactivation of p53 is found in up to
50% of tumors, and the application of gene transfer techniques
for replacement of function is presently under experimental
evaluation (3). For an appreciable fraction of gliomas, however,
the finding of responsible genes is still elusive.
EGR-1 (also known as NGFI-A, TIS8, Krox-24, and Zif268)
is a member of the immediate early genes family and encodes a
nuclear phosphoprotein involved in the regulation of cell growth
and differentiation in response to signals such as mitogens,
growth factors, and stress stimuli (4–7). However, in other
circumstances, EGR-1 is induced very early in the apoptotic
process (8), where it mediates the activation of downstream
regulatory genes such as p53 and tumor necrosis factor 
(9, 10).
In contrast with these functions, previous studies have
shown that EGR-1 is down-regulated in several types of neo-
plasia, suggesting a role as a tumor suppressor gene in analogy
with WT-1, another family member which binds to a similar
DNA motif (11, 12). For example, EGR-1 has been found to be
decreased or undetectable in human breast and small cell lung
tumors (13, 14) as well as in an array of tumor cell lines (11, 15,
16). Gene deletion or mutations have also been reported in
sporadic cancer cases (17). Moreover, reexpression of EGR-1
suppresses the growth of transformed cells both in soft agar and
in athymic mice (16). This is at least partially related to the
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induction of TGF-14 expression—a factor with an important
role in the progression of gliomas (18, 19). Similarly, studies
with antisense vectors indicated that the transformed phenotype
is enhanced by the inhibition of EGR-1 expression (20). These
studies suggest a consistent growth suppression role for EGR-1
in cells of neuroectodermal origin. Here, we directly test this
hypothesis by examination of the expression of EGR-1 in fresh
surgical specimens of glioblastomas and normal tissue.
EGR-1 has been implicated in the regulation of p53,
thereby providing an additional explanation for a suppressor
role (9, 10, 21, 22). The function of p53, in turn, is determined
in part by the Mdm2 protein and by an alternate reading frame
(ARF or p14ARF) product of the p16/INK4a locus. ARF binds
to Mdm2, allowing active p53 to accumulate in the nucleoplasm
(23). Indeed, homozygous deletion of the murine ARF gene in
mice leads to a similar phenotype as for inactivation of p53,
further indicating that ARF and p53 function in the same bio-
chemical pathway (reviewed in Ref. 24). Thus, deletion of ARF
or overexpression of Mdm2 may be functionally redundant
means of disrupting the ARF-Mdm2-p53 pathway. In 75% of
B-cell lymphomas that develop in myc-transgenic mice, there
occurs either a mutation in p53, deletion of ARF, or overexpres-
sion of Mdm2, but not more than one of these alterations (25).
Similarly, in humans, p53 is itself mutated in 50% of cancers,
whereas deletion of ARF and amplification or overexpression of
Mdm2 occur in a high fraction of the remaining cases (24). This
mutational pattern is commonly manifested in human glioblas-
tomas as well (26–28). Therefore, to examine the relationship
between EGR-1 and p53, we also examined the genetic status of
p16INK4a, Mdm2, and p53 in the primary glioblastomas.
We find that EGR-1 expression was strongly reduced in fresh,
surgically derived brain tumors compared with normal brain tissue,
where the basal expression is high (reviewed in Ref. 29). EGR-1
was suppressed in 87% of the cases independent of whether
alterations in p16/INK4a and Mdm2 were present but significantly
less suppressed and more variable in tumors bearing p53 mutations.
These results indicate that loss of EGR-1 expression may provide
an important marker of glial cell malignancy.
MATERIALS AND METHODS
Tissue Samples. We examined 31 tumors from astrocy-
toma (astrocytic tumors grades I-III) or glioblastoma (astrocytic
tumors grade IV) patients at Instituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy, an
affiliated clinic of the University of Rome “La Sapienza.” Donor
patients were restricted to those not treated previously with
chemotherapy or radiation therapy. Tumor samples were col-
lected from zones free of any necrotic tissue at the time of the
initial “debulking” surgery and processed immediately. One
aliquot of each tissue was fixed in 10% formalin for histological
analyses and grading. Another aliquot was frozen at 70°C for
DNA, RNA, and protein extraction. A third aliquot was fixed
overnight in 4% paraformaldehyde (pH 7.2) and used for par-
affin embedding. The remainder was frozen in liquid nitrogen.
Several human specimens of normal white and gray matter were
obtained either from adult patients that were being treated
surgically for refractive drug-resistant epilepsy or within 8 h
postmortem from subjects of accidental death. A sample of
human total RNA from normal adult brain was purchased from
Invitrogen (Carlsbad, CA). Primary astrocytes were prepared
from the whole brain of neonatal Wistar rats as described (30).
Regulatory Affairs. The Institutional Ethics Board ap-
proved the experimental design and scope of this study. All
subjects provided a written informed consent for this study.
Only tissue excess to diagnostic and patient management needs
was made available for research.
Isolation and Northern Analysis of Total RNA. Total
RNA was extracted from tumor pieces (50 mg) using the Ultra-
spec RNA isolation system (Biotecx Laboratories, Houston, TX).
For Northern analysis, 20 g of denaturated RNA was used for
each sample and processed as described previously (15). Levels of
EGR-1 expression in control and cancer patients were expressed as
means  SE and compared using the t test, ANOVA, and non-
parametric Mann-Whitney U test. All tests were two-sided, with a
critical level for significance defined as P  0.05.
DNA Extraction and Analysis. For Southern analysis,
20 g of high-molecular weight DNA was digested with 50
units of TaqI, electrophoretically separated in 0.8% agarose gel,
and transferred to nylon membranes, as above. Membranes were
hybridized with DNA probes labeled with [32P]dATP by ran-
dom priming. The GAPDH probe was a 1.3-kb, full-length
cDNA clone encoding rat GAPDH (31). A 1.6kb BglII fragment
from pCMV-EGR-1 plasmid was the probe for EGR-1 (32),
corresponding to the coding region of the mouse cDNA. The
DNA probes for MTS1/p16, a 514-bp fragment corresponding to
exon 2 of the MTS1 gene, and for Mdm2, bases 53–653 of the
human Mdm2 cDNA sequence, were generated by PCR ampli-
fication as described (33, 34). The identity of the generated
probes was corroborated by restriction-enzyme analysis. The
probe for HTSHR was the 2.5kb EcoRI fragment from the
pBabeTSHR plasmid (35) corresponding to the full-length
cDNA for HTSHR. The Mdm2, MTS1, and HTSHR probes
identify 8.0- and 5.5-kb, 3.3-kb, and 4.2- and 1.9-kb bands,
respectively.
DNA Sequencing of p53 Exons 5–9. For analysis of p53
mutations, three DNA fragments (containing exons 5 and 6,
exon 7, and exons 8 and 9, respectively) were PCR-amplified
from genomic DNA by using primers described previously (36).
Direct sequencing was performed with a ABI PRISM 377
DNA Sequencer using the DNA Sequencing kit, Big Dye Ter-
minator (PE Applied Biosystems, Inc., Boston, MA) according
to the manufacturer’s instructions. The results were analyzed by
means of the ABI sequencing analysis software.
Densitometric Analysis and Allele Dosage. Densito-
metric scans of Northern and Southern results were elaborated
using the NIH Image software.5 For Northern analysis, the
4 The abbreviations used are: TGF-1, transforming growth factor 1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HTSHR, human
thyrotropin receptor; NBA, astrocytes from newborn rat brain; WM,
human white matter; TB, human total brain; GFAP, Glial fibrillary
acidic protein; MTS 	 1, multiple tumor suppressor 	 1. 5 Available on the Internet at: http://rsb.info.nih.gov/nih-image.
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EGR-1 signals were normalized to the expression of the
GAPDH gene of each sample, probed on the same membranes.
Allele dosage was measured and calculated as described (34).
Hybridization signals were normalized to the values observed at
the control locus HTSHR on the same membrane. Mdm2 ampli-
fication is defined as at least five copies of gene/cell. Loss of
heterozygosity at the p16INK4a locus was defined as a 40%
decrease in the densitometry value (37).
Immunohistochemistry. A rabbit polyclonal antibody
against EGR-1 (Santa Cruz Biotechnology, Santa Cruz, CA) and
a mouse monoclonal antibody against GFAP (Sigma Chemical
Co., St. Louis, MO) and p53 (PharMingen, Heidelberg, Ger-
many) were used for staining. Peroxidase-conjugated secondary
antibodies were localized with the aid of an ABC Universal
Quick kit (Vector Laboratories, Burlingame, CA) following the
manufacturer suggested procedure.
RESULTS
EGR-1 Is Down-Regulated in Malignant Brain Tumors.
Thirty-one fresh glioma biopsies were obtained from patients
diagnosed with astrocytoma (n 	 9) or with glioblastoma (n 	
22) and frozen in liquid nitrogen immediately upon resection.
Tumor staging and grade were established according to WHO
classification. To evaluate EGR-1 expression levels, three dif-
ferent normal sources of mRNA, including fresh preparations of
NBA and WM, were analyzed. In addition, a commercial RNA
from TB was investigated. Each tumor sample was evaluated at
least twice and normalized to the level of GAPDH expression of
the same sample. All RNAs of normal brain investigated exhib-
ited a steady-state level of EGR-1 expression within a close
range of values (Fig. 1). As a reference value for basal EGR-1
steady-state mRNA level, the intermediate level of expression of
NBA2 was taken as 100%.
Steady-state EGR-1 mRNA levels are significantly
down-regulated in both astrocytomas and glioblastoma
groups compared with normal tissue (Fig. 1). Mean values (
SE) are 88.0 ( 9.6) in normal brain tissue, 14.7 ( 5.1) in
astrocytomas (P  0.005 versus normal), and 33.6 ( 10.0)
for the 22 glioblastoma cases (P  0.01 versus normal). Most
glioblastomas, 87%, are tightly clustered within an expres-
sion level of less than one-fourth of the reference tissue.
However, four glioblastoma cases exhibited mRNA levels
comparable with or even greater than those of normal tissue,
suggesting a bimodal distribution within the glioblastoma
multiforme group. Other distinguishing features of this high
expression group are noted below. Examples of Northern
analysis for the various tumors and normal brain samples are
shown in Fig. 2.
We also carried out Western analysis (data not shown), and
we observed that basal EGR-1 protein is undetectable in most
cases, similar to the observations of mRNA. However, several
exceptions that exhibit high levels of EGR-1 protein, such as
tumor cases T15 and T36 were noted. Thus, the circumstances
associated with EGR-1 expression were investigated in greater
detail.
EGR-1 protein expression and localization in normal
human brain tissue and in the gliomas was investigated by
immunocytochemistry (Fig. 3). Similar to mRNA, EGR-1
was less apparent in tumors compared with normal astrocyte
populations. In normal subpial and white matter astrocytes,
EGR-1 expression was readily apparent and widely distrib-
uted. Within cells, EGR-1 was localized to the cell nucleus.
Within nuclei, EGR-1 was either diffuse or limited to nuclear
membrane in most cases. Cortical neurons were strongly
positive with a nuclear localization similar to that of astro-
Fig. 1 Quantification of EGR-1 expression in fresh glioma biopsies by
Northern blot as compared with normal brain tissue. EGR-1 mRNA
levels are down-regulated in glioma. The EGR-1 mRNA levels were
determined by densitometry and expressed as a percentage of normal
(NBA2). Three different groups of data are shown: normal brain (5
cases), astrocytoma (9 cases), glioblastoma (22 cases). E, cases carrying
mutated copies of the p53 gene. For each group of data, the mean  SE
is represented. The mean values of astrocytomas [P  0.005 ()] and
glioblastomas [P  0.01 ()] differ significantly from normal tissue.
Fig. 2 Northern analysis of EGR-1 expression in representative cases
of fresh human malignant glioma compared with normal controls. As a
nucleic acid probe for EGR-1 RNA, a 1.6-kb BglII fragment from the
cDNA coding sequence of the mouse gene was used. This fragment
shows an 87% sequence similarity to the human homologue. Represent-
ative tumor biopsies are indicated as T (with numeral). Three different
controls are included in this blot: one sample of NBA (NBA1) and WM
(WM) and one of TB (TB1). These same RNAs were included as
cross-reference controls in each independent experiment. Blots were
rehybridized with a GAPDH probe. Exposure times for the EGR-1- and
GAPDH-hybridized filter shown are 72 and 12 h, respectively.
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cytes (Fig. 3, c and d). GFAP staining was performed to
identify the astrocyte population in gray and white matter
(Fig. 3, a and b). To our knowledge, this is the first obser-
vation of EGR-1 protein in normal human brain tissue.
The analysis of the pattern of EGR-1 protein expression
in tumors with varying levels of EGR-1 mRNA showed that
all tumor biopsies with levels of EGR-1 RNA expression
from 15–200% relative to NBA2 (Fig. 1) stained positively
for EGR-1 protein. However, the fraction of positive cells for
each tumor ranged from around 13% to no more than 30%.
Conversely, efforts to detect EGR-1 protein were, as a rule,
negative in all sections from those tumors showing deficient
mRNA expression, although the presence of a few EGR-1-
positive cells, accounting for 2% of the total cell popula-
tion, could be observed. Inasmuch as EGR-1 is highly ex-
pressed in normal brain and because gliomas are highly
infiltrating tumors, it might not be infrequent that normal
cells are found mixed within the tumor population. For these
reasons, we suspect that the amount of RNA and protein
found in the tumors investigated here might be overesti-
mated. Moreover, we cannot rule out that stable EGR-1
protein derived from the normal cells that occur in low-grade
Fig. 3 Localization of EGR-1 in normal human
brain tissue and in fresh human malignant glio-
mas with wild-type or mutant p53. GFAP (a and
b) and EGR-1 (c and d) are stained by immu-
nohistochemistry in human brain sections from
white (a and c) and gray matter (b and d).
EGR-1 protein is associated preferentially with
nuclear membrane in both astrocytes from white
and gray matter and neurons (gray matter). Ex-
pression pattern of EGR-1 and p53 in tumor
astrocytes. EGR-1 (e and g) and p53 (f and h)
are stained by immunohistochemistry in contig-
uous sections from p53-mutated (e and f) and
wild-type tumors (g and h).
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astrocytomas, such as cases T15 and T36, may cause the
relatively high EGR-1 protein measurements observed in
these cases. In conclusion, our in situ studies provide an
explanation for the variation of EGR-1 protein expression in
tumors that exhibit an overall suppression of mRNA and
provide support for the general correlation of low levels of
EGR-1 mRNA in fresh tumor tissue and a parallel decrease in
protein accumulation.
Frequency and Spectrum of p53 Gene Mutations. Re-
cent reports suggest that EGR-1 can induce the transcription
of the p53 gene leading to increased apoptosis of tumor cells
and that, conversely, EGR-1 expression may be influenced by
the level of p53 (9). These observations suggest, as one
hypothesis, that suppression of EGR-1 may serve to augment
the survival properties of astrocytic tumors by blocking, at
least in part, the induction of p53 or by blocking a p53-
related function. Therefore, we sought to determine whether
p53 gene status correlates with the EGR-1 expression level
within the same samples.
The p53 gene was characterized by examining the nucle-
otide sequences of exons 5–9 for the presence of mutations.
Among the 31 patients examined, 10 mutations were found
(2 astrocytomas and 8 glioblastomas), as summarized in
Table 1. Briefly, two mutations were located in exon 5, three in
exon 6, three in exon 7, and two in exon 8, all mutations
resulting in an amino acid substitution. Three mutations were
found in the L domain, and two in the LH domain. The
L (codons 236–251) and LH (codons 163–195) domains are two
loop-based elements that bind to DNA. Another mutation (T33)
is located at LSH, a third loop-based p53 domain. As reported in
the literature, for most tumors, more than two-thirds of missense
mutations are found in L, LH, or LSH (38).
More than half of the mutations found in our tumors
probably inactivate the protein, because they fall into highly
conserved structural motifs. These are indicated in Table 1 as
“I.” All mutations observed here were already found in tumors
of different histological type,6 except for T26 and T40, which
bear mutations reported here for the first time.
6 IARC TP53 Mutation Database, Internet address: www.IARC.FRX.
Table 1 Summary of mutations found in a series of 31 astrocytic tumors
Case Diagnosis Exon Codon
p53
mutation Substitution
Mdm2
DNA
Egr-1 RNA
(% normal)
P16
genotype
T26 Ga 6 213 C3G Arg3Gly N 200 
/

T21 G 5 152 C3T Pro3leu N 100 
/

T28 G 7 241 C3T Ser3Phe Ib N 90 
/

T46 G 7 241 C3T Ser3Phe I N 75 
/

T2 A 6 216 G3A Val3Met N 12 
/

T7 G 7 237 G3A Met3Ile I N 30 
/

T15 A 5 175 G3A Arg3His I N 20 
/

T33 G 8 278 C3T Pro3Leu I N 36 
/

T40 G 6 193 A3T His3Leu I N 24 
/

T48 G 8 266 G3C Gly3Arg N 35 
/

Av: 66
T27 G No change Amplified 30 
/

T31 G No change Amplified 15 
/

T45 G No change Amplified 13 
/

Av: 19
T1 G No change N 0 del/del
T3 G No change N 5 del/del
T11 G No change N 2 del/del
T16 G No change N 10 
/del
T36 G No change N 0 del/del
Av: 3
T13 G No change N 25 
/

T14 G No change N 0 
/

T18 A No change N 30 
/

T19 A No change N 10 
/

T25 G No change N 8 
/

T32 G No change N 12 
/

T42 A No change N 0 
/

T44 A No change N 45 
/

T5 A No change N 0 
/

T6 A No change N 0 
/

T9 G No change N 30 
/

T10 G No change N 0 
/

T12 A No change N 15 
/

Av:
13
a G, glioma; A, astrocytoma; N, normal genotype; del, deleted allele; Av, mean percentage.
b I, mutation with probable inactivating function. These mutations fall into highly conserved structural motifs.
2792 EGR-1 Down-Regulation in Human Glial Tumors
Loss of EGR-1 Expression Is Frequent in Tumors
Carrying a Conserved p53 Pathway. By comparing the
levels of EGR-1 mRNA in the 21 tumors bearing wild-type
copies of the p53 gene with those present in samples with the
mutated gene (Table 1), we noticed that EGR-1 expression is
significantly higher in p53-mutated tumors. The average val-
ues of EGR-1 mRNA in the two groups were 11.9% ( 2.9)
and 62.2% ( 18.1) compared with normal values, respec-
tively (P 	 0.001, according to Student’s t test; and P 	
0.0002, as evaluated by Mann-Whitney nonparametric U
test). Moreover, in the subset of four tumors with mutated
p53 responsible for the bimodal expression of EGR-1 mRNA
of the glioblastoma multiforme (Fig. 1), the average RNA
expression is 116%, or very similar to that of normal tissue.
Thus, the pattern of results is consistent with marked sup-
pression of EGR-1 mRNA levels in tumors bearing wild-type
p53, whereas EGR-1 is significantly less suppressed in the
group bearing a mutated p53 gene or not suppressed at all as
in a subset of the tumors with a mutated p53 gene.
These results were also confirmed by the evaluation of p53
intracellular protein levels, which are known to accumulate in
cells carrying the mutated gene. Indeed, we examined both the
expression of EGR-1 (Fig. 3e) and the accumulation of p53
protein by immunohistochemistry on contiguous tumor sections
from tumor biopsies carrying mutations in the p53 gene (Fig.
3f). The expression of EGR-1 and p53 was also examined in
tumors carrying wild-type copies of the tumor suppressor gene
as a control (Fig. 3, g and h). Labeled p53 protein was demon-
strated in all sections from the tumors with mutated p53 but not
in sections from wild-type p53. The frequency of cells found in
glioma specimens that were expressing p53 and/or EGR-1 is
graphically reported in Fig. 4. EGR-1 expression significantly
overlapped with p53 accumulation in all three examined tumors
with mutated p53 (correlation coefficient rPearson 	 0.86; P 	
0.0067). All of the four tumors that showed 10% EGR-1
positive cells had undetectable levels for EGR-1 mRNA expres-
sion. Thus both the mRNA analysis and immunohistochemical
analysis indicated a consistent pattern of significantly elevated
EGR-1 mRNA and protein expression in tumors lacking wild-
type p53.
Determination of Alterations of Mdm2. The Mdm2
protein is an important p53 antagonist and, therefore, a potential
indirect regulator of EGR-1 expression (24). Allele dosage
determination of the Mdm2 gene was undertaken for all 31
glioma biopsies by quantifying the Mdm2 Southern analyses
hybridization intensities. Three tumor biopsies of glioblastoma
(T27, T31, and T45) were found containing amplified copies of
Mdm2 (Fig. 5A). The allele dosage ratios ranged from 25-fold
to 50-fold in the case of T27. All three of these tumors expressed
a wild-type p53 gene (Table 1).
The finding of cases of amplified Mdm2 genes only among
tumors carrying wild-type copies of the p53 gene suggests that the
fraction of tumors showing impaired p53 function might be larger
than could be estimated from the net number of cases showing p53
mutations. Therefore, we also evaluated the differences for the
EGR-1 mRNA values shown above by including within the group
of patients with p53 mutations the tumors with Mdm2 mutations.
Again, we confirmed that EGR-1 expression is significantly lower
in nonmutated tumors: 10.7  3.2% versus 52.3  14.8% (P 	
0.003, according to Student’s t test; and P	 0.0002 as evaluated by
Mann-Whitney nonparametric U test). In conclusion, all astrocytic
tumors investigated here either were carrying mutations for the p53
or Mdm2 genes or presented strongly reduced levels of EGR-1 gene
expression (the EGR-1 mRNA mean value calculated from all but
mutated cases is 13.5  4.1%).
Analysis of Alterations of p16 Gene. Deletions of
INK4a, also known as p16, are commonly associated with
deletion of the alternate reading frame product, ARF, an Mdm2
antagonist (39, 40). We investigated the p16 gene in our panel
of glioma biopsies by Southern blot hybridization and deter-
mined gene dosage, as done above for Mdm2. Single allele or
homozygous deletions were found in 1 (T16) and 4 (T1, T3,
T11, and T36) cases, respectively (Fig. 4B). All occurred in
Fig. 4 Allele dosage for Mdm2 and p16INK4a genes as determined by
Southern analysis in representative tumor samples. A, 3 tumors (T45,
T31, and T27) show amplified copies of the Mdm2 gene. B, 5 tumors
(T36, T24, T11, T3, and T1) show absence of both alleles of p16/MTS1.
Tumor T16 shows single-allele deletion. C, the same filter as in A and
B hybridized with a probe from the HTSHR gene (HTSHR), for signal
normalization.
Fig. 5 EGR-1 expression correlates with p53 in mutated gliomas. Im-
munohistochemical evaluation of the percentage of EGR-1-positive cells
in tissues from tumors carrying wild-type p53 (F) or mutated copies of
the gene (E). Staining of the p53 protein was demonstrated in all
sections from the mutated tumors but not in sections from wild-type-p53
tumors. The percentage of EGR-1-positive cells significantly overlapped
the percentage of cells showing p53 protein accumulation in all of the
three p53-mutated tumors investigated (correlation coefficient rPearson	
0.86; P 	 0.0067).
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glioblastomas that expressed a wild-type p53 and had no Mdm2
abnormalities (Table 1), indicating a strictly mutually exclusive
pattern of change among these three types of gene changes.
Moreover, the cases with deleted p16 sequences and, therefore,
with normal p53 gene sequences, exhibited little or no EGR-1
mRNA expression, with an average of 3.4%. Furthermore, these
data suggest that reduced EGR-1 expression is a new molecular
marker of astrocytic tumors without genetic alterations impair-
ing the p53 pathway.
DISCUSSION
EGR-1 Is Suppressed in Astrocytic Tumors Compared
with Normal Tissue. Here we have collected and evaluated
31 cases of fresh human astrocytomas or glioblastomas and have
shown that EGR-1 expression is significantly decreased in tu-
mor biopsies compared with a series of control tissues derived
from normal brain, either human or rat. EGR-1 gene expression
in glioma specimens is decreased at both RNA and protein
steady-state levels, and this finding is supported by the reduced
number of EGR-1-positive cells found in the tumor specimens
examined in situ. This phenomenon is common to both astro-
cytomas (WHO grade I-III) and glioblastoma. In the latter,
EGR-1 mRNA down-regulation is less marked. However, even
including these cases, the decreased expression of EGR-1 is still
significant compared with normal controls. These observations
on the expression of EGR-1 in vivo, therefore, support a number
of previous studies of human tumor cell lines (11) including
glioblastoma cell lines (11, 16), demonstrating that EGR-1 has
significant tumor suppressor properties.
The ARF-Mdm2-p53 Pathway Plays a Critical Role in
Glioblastomas. Previous studies of gliomas have shown that
inactivation alterations of the ARF-Mdm2-p53 pathway com-
monly occur in a mutually exclusive pattern with a combined
frequency ranging to 80% (25, 27, 28, 33, 39, 41). Indeed, we
find that 13 cases exhibited either p53 mutations or Mdm2
amplification but not both. Five cases exhibited a deletion of
p16, all with wild-type p53 and Mdm2 genotypes. Thus, the
changes in the ARF-Mdm2-p53 pathway occurred in a strictly
mutually exclusive pattern with a combined frequency of 58%.
It is important to note that we examined the presence or absence
of exon 2 of the p16 gene, which does not exclude the possibility
that a truncated ARF protein encoded by an intact exon 1
leading to functional exon 1 or exon 1 products may be
present. However, there seems to be no evidence that deletion of
exon 2 with expression of a functional truncated form occurs in
vivo. Moreover, in those cases where p16INK4a and ARF
deletion have been examined together in vivo, both are almost
always deleted together (26–28, 39–41). Thus, although it is
not possible to be unequivocal about the deletion of all forms of
the ARF protein, our observations are entirely consistent with
the conclusion that for gliomas, as for other major human
neoplasms, disruption of ARF or p53 or overexpression of
Mdm2 is a major mechanism of tumor progression.
EGR-1 Levels in Vivo Are High Only When p53 Is
Mutant. The major hypothesis of this study is that EGR-1 is a
tumor suppression factor and, therefore, would be inhibited in
expression in fresh brain tumors, as inferred from glioblastoma cell
line studies (16). Two major corollaries are that inhibition of
expression of EGR-1 would occur regardless of the state of the
ARF-Mdm2-p53 pathway if EGR-1 worked through a p53-inde-
pendent mechanism (i.e., EGR-1 mRNA absent in most cases), but
that inhibition of expression would occur only exclusive of other
changes in the ARF-Mdm2-p53 pathway if EGR-1 acted as an a
member of the pathway (i.e., EGR-1 mRNA absent only exclusive
of other p53 pathway inactivating changes). Surprisingly both
corollaries are manifested. EGR-1 mRNA expression is reduced or
absent in 87% of all cases, and the extent of reduction, to 15% of
normal, was shown to be significant even when the average for all
31 tumor cases is compared with the normal value. This conclusion
is supported by direct immunohistochemical analysis of protein
expression. Thus significant inhibition of expression regardless of
the state of the ARF-Mdm2-p53 pathway is observed. On the other
hand, EGR-1 mRNA expression is notably higher for the cluster of
cases with p53 mutations (average, 66% versus 19% and 3.4% for
the cases with altered Mdm2 and p16 genes, respectively), and the
values are much more variable, ranging to 200% of the normal
value (Table 1). Indeed, the average level of expression for this
group was shown to be significantly increased compared with all
other cases. Thus, strong inhibition of expression of EGR-1 is
exclusive of the group of cases with mutations in p53. Because
most mutations observed here are thought to inactivate p53 (com-
pare Table 1), this observation suggests that the mechanism of
action of EGR-1 is not entirely independent of that for inactivation
of p53 itself. Thus, during tumor progression, there appears to be
reduced pressure to inhibit expression of EGR-1 when p53 has been
inactivated. A model that provides an explanation of these effects
is considered below.
What Is the Mechanism of Tumor Growth Suppression
Operated by EGR-1? Much of the previous experimental
evidence of the oncosuppressive activity of EGR-1 is based
on the effects of constitutive reexpression of the gene in
several tumor cell lines, including the glioblastoma U251 cell
line (11, 16, 18), and by the suppression of expression of
EGR-1 in human tumor cell lines (13, 42). The reexpression
of EGR-1 leads to restoration of contact inhibition, morpho-
logical reversion, and the reduction in tumorigenicity (16).
Most of these changes are referable to up-regulation of
TGF-1 because of direct transactivation of TGF-1 by
EGR-1. In fact, TGF-1 is expressed and secreted in direct
proportion to the level of expression of EGR-1 (16), and the
effects of EGR-1 are reversed by the addition of anti-TGF-1
antibodies (18). Indeed, TGF-1 is recognized as a major
growth regulator of naturally occurring gliomas, and inacti-
vation of the TGF-1 mechanism, especially by loss or
mutation of the TGF-1 receptor type II subunit, increases in
frequency with the increasing grade of gliomas (19). This
view is supported also by preliminary studies conducted in
vitro by our group on an extended series of freshly explanted
gliomas in which we observed a strong correlation between
TGF-1 secretion and EGR-1 expression.
These observations suggest a model for the suppressor role
of EGR-1 and how this factor may be related to the p53 mech-
anism. Both p53 and the TGF-1 signal transduction path-
ways regulate the same target gene, the cell-cycle regulator
p21Cip/1Waf1 (43, 44). Therefore, by directly transactivating the
TGF-1 promoter (18–42) and stimulating the secretion
and subsequent activation of TGF-1, EGR-1 may regulate
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p21Cip/1Waf11 via an autocrine loop. Thus, EGR-1 itself may be
a target of suppression during tumor progression, as for p53
and/or the TGF-1 receptor. However, if p53 is the major
regulator of p21Cip/1Waf1 expression, tumor cells that first
undergo complete inactivation of p53 may be relatively insen-
sitive to the inhibition of EGR-1 expression. This mechanism
provides an explanation for the bimodal distribution of EGR-1
mRNA, i.e., that relatively high mRNA values segregate with
p53 mutations (compare Table 1). In summary, we propose that
EGR-1 acts in human glioma as a tumor suppressor factor.
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